Amryt Pharma PLC (LON:AMYT)‘s stock had its “speculative buy” rating reaffirmed by research analysts at Beaufort Securities in a research report issued to clients and investors on Tuesday. They presently have a GBX 65 ($0.85) price objective on the stock. Beaufort Securities’ price target would suggest a potential upside of 265.99% from the stock’s previous close.
Separately, Shore Capital dropped their price target on shares of Amryt Pharma PLC from GBX 86 ($1.13) to GBX 70 ($0.92) and set a “house stock” rating for the company in a research report on Thursday, September 21st.
Shares of Amryt Pharma PLC (AMYT) opened at GBX 17.76 ($0.23) on Tuesday. Amryt Pharma PLC has a 12-month low of GBX 13.44 ($0.18) and a 12-month high of GBX 29.50 ($0.39).
Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.
Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.